Clinic-in-the-Loop - by Ruxandra Teslo and Asimov Press
Clinical trials are engines for scientific discovery. Better drugs require not just more trials, but also improved data collection, to create therapeutic feedback loops.
For the last several years, I have been trying to understand why biomedical progress, especially in therapeutics, has become less productive despite staggering advances in basic science. I am not the only person vexed by this. In 2012, biotechnologist Jack Scannell formally described the dwindling returns on therapeutic investments, coining the term Eroom’s Law (Moore’s Law in reverse). Eroom’s law states that the inflation-adjusted cost to bring a new drug to market roughly doubles every nine years: a trend that has held since the 1950s. With the goal of upending Eroom’s law, I have spent…
saved by
related reading
- Clinic-in-the-Loopasimov.press
- Cure all diseasesworksinprogress.news
- Eroom's law - Wikipediaen.wikipedia.org
- Intelligence is not the main bottleneck - by Ruxandra Teslowritingruxandrabio.com
- AI Versus Eroom's Lawsubstack.com
- Why is progress in biology so slow?sam-rodriques.com
- Slow, Costly Clinical Trials Drag Down Biomedical Breakthroughsmanhattan.institute
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- What will it take for AI to change drug discovery?writingruxandrabio.com
- Creating therapeutic abundancesubstack.com
- The closed-loop manifestojakefeala.substack.com